The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol
Open accessAbstract
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is associated with substantial morbidity, despite drug therapy. Interferon-gamma, a cytokine produced mainly by CD4 T lymphocytes, can activate alveolar macrophages, important effector cells in host immunity against Mycobacterium tuberculosis. We investigated safety and tolerability of aerosolised interferon-gamma in patients with MDR-TB, and assessed its efficacy in terms of sputum-smear grades. METHODS: We did an open-label trial of aerosol interferon-gamma given to five patients with smears and cultures positive for pulmonary MDR-TB, despite documented adherence to therapy. The patients received aerosol interferon-gamma 500 micrograms three times a week for 1 month. Safety and tolerability were assessed, and, as well as routine clinical assessments, sputum samples for smear and culture were collected at entry and weekly. Computed tomography scans of the chest were done at baseline and after therapy ended. FINDINGS: Interferon-gamma was well tolerated by all patients. In all five, bodyweight stabilised or increased. Sputum acid-fast-bacillus smears became negative in all patients, and the time to positive culture increased (from 17 to 24 days, not significant), which suggested that the mycobacterial burden had decreased. The size of cavitary lesions was reduced in all patients, 2 months after treatment had ended. INTERPRETATION: Preliminary data suggest that aerosol interferon-gamma is a well-tolerated treatment that may be useful as adjunctive therapy in patients with MDR-TB who are otherwise not responding well to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., & Stewart, T. A. (1993) · Science · doi:10.1126/science.8456300 · Cited by 1,727
Immune Response in Mice that Lack the Interferon-γ Receptor
Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., Vilček, J., Zinkernagel, R. M., & Aguet, M. (1993) · Science · doi:10.1126/science.8456301 · Cited by 1,548
Requirement for Transcription Factor IRF-1 in NO Synthase Induction in Macrophages
Kamijo, R., Harada, H., Matsuyama, T., Bosland, M., Gerecitano, J., Shapiro, D., Le, J., Koh, S. I., Kimura, T., Green, S. J., et al. (1994) · Science · doi:10.1126/science.7510419 · Cited by 844
A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
The International Chronic Granulomatous Disease Cooperative Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199102213240801 · Cited by 830
Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin
Goble, M., Iseman, M. D., Madsen, L. A., Waite, D., Ackerson, L., & Horsburgh, C. R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280802 · Cited by 698
Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis
Chan, J., Tanaka, K., Carroll, D., Flynn, J., & Bloom, B. R. (1995) · Infection and Immunity · doi:10.1128/iai.63.2.736-740.1995 · Cited by 407
Activation of human macrophages. Comparison of other cytokines with interferon-gamma.
Nathan, C. F., Prendergast, T. J., Wiebe, M. E., Stanley, E. R., Platzer, E., Remold, H. G., Welte, K., Rubin, B. Y., & Murray, H. W. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.2.600 · Cited by 359
Holland, S. M., Eisenstein, E. M., Kuhns, D. B., Turner, M. L., Fleisher, T. A., Strober, W., & Gallin, J. I. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301904 · Cited by 302
Pfyffer, G. E., Kissling, P., Jahn, E. M., Welscher, H. M., Salfinger, M., & Weber, R. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.4.834-841.1996 · Cited by 166
Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy.
Park, M. M., Davis, A. L., Schluger, N. W., Cohen, H., & Rom, W. N. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.1.8542137 · Cited by 161
Self-citation
Cited by
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 831
Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases
Kak, G., Raza, M., & Tiwari, B. K. (2018) · Biomolecular Concepts · doi:10.1515/bmc-2018-0007 · Cited by 617
Ehrt, S., Schnappinger, D., Bekiranov, S., Drenkow, J., Shi, S., Gingeras, T. R., Gaasterland, T., Schoolnik, G., & Nathan, C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1123 · Cited by 459
The Host Immune Response to Tuberculosis
SCHLUGER, N. W., & ROM, W. N. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.3.9708002 · Cited by 428
Self-citation
Metadata
- Authors
- Condos, R., Rom, W. N., & Schluger, N. W.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1997-05
- Volume
- 349
- Issue
- 9064
- Pages
- 1513-1515
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2108374918
- Cited by
- 316
- References
- 14
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. https://app.cochat.ai/papers/10.1016/s0140-6736(96)12273-x
- The paper
- Condos, R., Rom, W. N., & Schluger, N. W. (1997). Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. The Lancet. https://doi.org/10.1016/s0140-6736(96)12273-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.